Figure 5.
Concordance testing of IC50 values for anti-Wolbachia activity and host cell toxicity across a set of 20 compounds from the A∙WOL drug discovery program. (A) Anti-Wolbachia IC50 values in A·WOL legacy screens versus acumen screen at AstraZeneca. (B) Toxicity IC50 values in legacy versus EnVision screen at AstraZeneca. (C) acumen anti-Wolbachia IC50 values for occasion 1 versus occasion 2 in the AstraZeneca screen. (D) EnVision toxicity IC50 values for occasion 1 versus occasion 2 in the AstraZeneca screen.